Company news
Cizzle Biotechnology Holdings Plc (LSE:CIZ) news
Cizzle Biotechnology Holdings Plc news releases on 6ix. Latest, Sep 30, 2026: Interim Results
Press releases & updates
Interim Results
September 30, 2026
Laboratory Expansion to Accelerate Sales in USA
August 3, 2026
Update on Sales in USA
July 22, 2026
Half Year Operational Update
July 15, 2026
Change of Corporate Broker
June 30, 2026
CIZ1B Test Approved For Clinical Use in USA
June 16, 2026
Patent Granted in USA
June 12, 2026
Issue of Options, Salary Waivers, Incentive Plan
May 7, 2026
Conversion of Convertible Loan Notes
May 6, 2026
Final results for the year ended 31 December 2025
April 30, 2026
£250,000 Funding Facility
April 2, 2026
Progress on Launch of Biomarker Test in USA
February 23, 2026
Patent Granted in Canada
February 4, 2026
£250,000 Convertible Loan Note Issue
November 5, 2025
LOI with leading UK Clinical Diagnostic Group
November 5, 2025
Change of Registered Office
October 27, 2025
Interim Results
September 30, 2025
Update on Clinical Laboratory Partnerships in USA
September 29, 2025
Commercial Progress in USA
August 18, 2025
Result of AGM
June 30, 2025
Notice of AGM
June 6, 2025
Holding(s) in Company
May 28, 2025
£150,000 Convertible Loan Note Issue
May 20, 2025
Final results for the year ended 31 December 2024
April 30, 2025
Contract in Caribbean and Update on CIZ1B
April 28, 2025
Launch of New Website
April 14, 2025
Appointment of Non-Executive Director
March 25, 2025
Update on Launch of CIZ1B Biomarker Assay
March 24, 2025
Appointment of Professor Dawn Coverley as CSO
January 2, 2025
Update on Strategic Partnership in North America
December 16, 2024
Execution of Agreement for North America
October 21, 2024
Update on Licensing and Partnership Agreement
October 3, 2024
Collaboration with Moffitt Cancer Center
September 9, 2024
Manufacturing Agreement with BBI Solutions
July 18, 2024
Issue of Share Options in Lieu of Consultancy Fees
July 9, 2024
Update on North American Strategic Licensing MoU
June 17, 2024
Notice of Annual General Meeting
June 3, 2024
Final results for the year ended 31 December 2023
April 30, 2024
Licensing and Partnership MoU for North America
April 2, 2024
Placing to raise £0.62 million
March 26, 2024
Update on Put Option with Conduit
September 21, 2023
Completion of Evaluation Programme with Bio-Techne
September 19, 2023
Extension of and update on Put Option with Conduit
September 8, 2023
Expansion of Research Agreement and CIZ1B Update
August 10, 2023
Total Voting Rights
June 30, 2023
Subscription to raise £350,000
June 12, 2023
Posting of Annual Report and Notice of AGM
June 5, 2023
Update on Royalty Sharing Agreement in AZD1656
May 15, 2023
Results for the year ended 31 December 2022
April 27, 2023
New Research Agreement with the University of York
April 24, 2023